KV Enjoined From Making, Shipping Unapproved Drugs

Law360, New York (March 2, 2009, 12:00 AM EST) -- KV Pharmaceutical Co. has entered into a consent decree with the U.S. Food and Drug Administration that permanently enjoins the company, its subsidiaries Ethex Corp. and Ther-Rx Corp., and its principal officers from making and distributing adulterated and unapproved drugs.

The injunction against St. Louis-based KV and the other defendants aims to prevent them from manufacturing and shipping drugs until the firm obtains FDA approval and will remain in place until the defendants sustain continuous compliance with the FDA's current good manufacturing practice and new drug...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.